

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 15, No. 15

August 19th, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- Medicare proposed CY MPFS
- Payment reform legislation introduced
- MACRA updates and resources
- ANCO's *ASCO Highlights 2016*
- ANCO's *3Q2016 Hematological Malignancies Update*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on September 2nd. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

CMS released the proposed CY2017 *Medicare Physician Fee Schedule* (MPFS) at www.federalregister.gov/articles/2016/07/15/2016-16097/medicare-program-payment-policies-under-the-physician-fee-schedule-medicare-advantage-pricing-data. It estimates that in CY2017 reimbursement for the hematology/oncology specialty is set to increase by 2%, though the impact on individual practices will depend on the mix of services provided. Read ASCO's initial summary of the proposed CY2017 MPFS at www.asco.org/advocacy-policy/asco-in-action/proposed-2017-medicare-physician-fee-schedule-rule-released; ACCC's summary and analysis is at mynetwork.accc-cancer.org/viewdocument/2017-cms-opps-and-pf; and, read ASH's summary at www.hematology.org/Advocacy/Policy-News/2016/6440.aspx. **Register and listen to Bobbi Buell's webinar entitled *Medicare Proposed Rule for 2017 and Other Issues*** (September 2, 9AM PT, cc.readytalk.com/registration/#/?meeting=n0h4jpuqikvp&campaign=bztndtjw6kox) and read Bobbi's analysis at www.anco-online.org/BBMPFS2017Analysis.pdf.

CMS recently provided additional clarification to MACs and providers regarding reimbursement for prolonged drug and biological infusions that are started in the office and that are associated with care that is billed incident to a physician service using an external pump. Go to MLN Matters SE1609 at www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE1609.pdf for detailed information.

The *Community Oncology Alliance* supports S3211, the *Cancer Care Payment Reform Act of 2016*, that would establish a national Oncology

Medical Home demonstration project for payment reform under the Medicare program. (This legislation parallels HR1934 introduced in the House.) The purpose of the bill is to change the way Medicare pays for cancer treatment in order to provide well-coordinated, high-quality care that results in lower overall costs to cancer patients and the health care system. Read more about S3211 at www.communityoncology.org/2016/07/15/july-14-supports-new-oncology-payment-reform-bill-by-senators-cornyn-and-carper/. **ASCO supports HR5122, legislation that would halt CMS from implementing the CMS Medicare Part B drug reimbursement experiment and helps to keep the pressure on the Administration to withdraw or substantially change the experiment, and urges the House to pass it in a timely manner.** Please ask your Representative to co-sponsor HR5122 today by visiting cqrcengage.com/asco/. For more information about CMS's proposed experiment, go to www.cancerexperiment.com.

CMS is considering moving the start date for select provisions and using shorter baseline reporting periods for MACRA based on stakeholder feedback. As proposed, MACRA redefines how Medicare will reimburse oncologists for care they provide starting in January 2019. However, because evaluation begins in less than six months (i.e., 2017), it is imperative that oncologists understand and prepare for this reimbursement change now. Medicare intends to pay each provider a different fee based on their value and performance. Providers will choose one of two pathways. Providers choosing the *Merit-Based Incentive Payment System* (MIPS) will be paid higher or lower fees for each service provided based on their Composite Performance Score. Providers choosing the *Advanced Alternative Payment Model* (APM) will participate in risk-based programs and receive a 5% bonus. **Services provided in 2017 will form the basis for payments in 2019 and the actions you take starting in January 2017 will result in a reduction of up to 4% or increase of up to 22% in your Medicare revenue in 2019. Go to www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra for more information, including new ASCO MACRA resources and educational events.** ASCO will present a free webinar entitled *Are You Ready for MACRA? Meaningful Use (Advancing Care Information) and Clinical Practice Improvement Activities* on August 30th

at 1PM. For more information and to register go to www.asco.org/macra. **Download ASCO's step-by-step guide to preparing for MACRA and Top Ten List for MACRA Readiness** at www.anco-online.org/ASCOMACRAPrep.pdf and www.anco-online.org/ASCOMACRATopTen.jpf, respectively. Read ASCO's comments on the proposed MACRA regulations at www.asco.org/advocacy-policy/asco-in-action/asco-submits-comments-proposed-macra-implementation-rule. **Listen to ACCC's webinar on MACRA** at attendee.gotowebinar.com/recording/viewRecording/2308644939852908546/4288900566134237187/execdir@anco-online.org. **Read ACCC's comments on the proposed MACRA regulations** at www.accc-cancer.org/advocacy/pdf/2016-ACCC-Comment-Letter-to-CMS-on-Proposed-MACRA-Rule.pdf. **Read COA's comments on the proposed MACRA regulations** at www.communityoncology.org/wp-content/uploads/2016/06/COA_CMS_MACRA_5517PR_Comment_Letter_FINAL.pdf. **CMA's MACRA resource center is at www.cmanet.org/macra**. **Read Bobbi Buell's analysis of the MACRA proposal** at www.anco-online.org/BBMacraAnalysis.pdf.

MACRA encourages the development of alternatives to the current Medicare fee-for-service payment system as a means to achieve higher quality and more affordable care. ASCO believes that its *Patient-Centered Oncology Payment* (PCOP) model meets MACRA's definition of an alternative payment model (APM) and will actively advance PCOP as a certified APM. ASCO is offering practices a unique opportunity to test PCOP and will provide tools and assistance in modeling data to help practices be successful. To learn more about PCOP, please go to www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

CMA, MOASC, and State Legislative & Regulatory Issues

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership

is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The August 2016 edition includes:

- HealthNet Federal Services awarded Tricare contract beginning in late 2017
- Blue Shield implements system fix to correctly pay HPV9 claims
- Covered California announces plan offerings for 2017
- Anthem Blue Cross announces changes to reimbursement policies and claims software
- Last chance for providers to prevent deactivation by Medicare
- UHC to require prior authorization for select outpatient surgical procedures
- CMA publishes MACRA resource center and preparation checklist
- CMS releases proposed 2016 Medicare physician fee schedule
- DOJ files lawsuit to block two health insurance mega-mergers
- New online Medi-Cal provider enrollment portal launch planned for October 2016
- The Coding Corner: The essential facts about CPT modifier 33

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—SNFs: Final FY2017 Payment and Policy Changes; Hospice Benefit: Finally FY2017 Payment and Policy Changes; Physician Compare: 2014 Quality Data Available; PQRS: EIDM Accounts Required to Access Feedback Reports and 2015 Annual QRURs; ICD-10 Coding Resources *Events*—PQRS Feedback Reports and Informal Review Process for Program Year 2015 Results Call-August 10; Open

Payments: Limited Time for Physicians to Dispute 2015 Data
Claims, Pricers, and Codes—ICD-10 GEMS for 2017 Available; 2017 ICD-10-CM and ICD-10-PCS Code Updates;
Publications—Remittance Advice Information: An Overview Fact Sheet-Reminder; Physician Compare Call: Addendum-New; PECOS Technical Assistance Contact Information Fact Sheet-Revised

- CERT MAC Improper Payment Rates for 2014 and 2015
- Non Covered Services LCD-R12
- Timely Reporting of Provider Enrollment Information Changes SE1617
- Reopenings Update-Changes to Chapter 34 CR9639
- Medicare B News JE July 2016 Bulletin-Now Available
- MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease LCD-R2

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/workshops include:

- Understanding National and Local Coverage Determinations (August 30)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

Noridian/JEMAC reports that only 19% of physicians have responded to the most recent revalidation notices. It has resumed its regular revalidation cycle and encourages all providers to learn about their revalidation requirements at med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/provider-enrollment-revalidation-cycle-2. *Noridian/JEMAC* will soon be deactivating billing privileges for physicians who have not submitted completed applications to CMS.

DHCS/MediCal is surveying physicians for feedback on the effectiveness of DHCS/MediCal's fee-for-service provider relations activities, including the telephone service center, cash control unit, regional reps,

publications, and provider seminars/trainings. Learn more about the survey and participate at www.cmanet.org/news/detail/?article=practices-encouraged-to-take-dhcs-medi-cal.

Subscribe today to receive the DHCS/Medi-Cal Subscription Service (MCSS) via e-mail. The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go to the MCSS Subscriber Form (files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp) to subscribe.

A list of DHCS/MediCal webinars is at <https://learn.medi-cal.ca.gov>.

The *Anthem Blue Cross Network eUpdate* (August 2016) is now available online at www.anthem.com/ca/provider/f5/s3/t3/pw_g256090.pdf and features NOC oncology and biologic drugs, precertification changes, effective November 1, 2016; Enhancements to AIM Clinical Appropriateness Guidelines for advanced Imaging, effective November 1, 2016; and, Change to expansion of precertification requirements for radiation therapy fractions-revised date to October 31, 2016.

UnitedHealthcare's Network Bulletin (August 2016) is now available online at unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles entitled Communication Effectiveness Survey, CMS-required Model for Care Training Information, and Details of How to Use Your PCOR to Track Preventive Health Care Opportunities for Your Patients.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2016

Professional Education Meeting

ANCO hosted its 2016 professional education meeting on August 3rd at *The Claremont Resort*. The agenda included *MACRA—What It Is and How Oncology Practices Can Prepare*; *Managing Oncology within Medicare*; *California's End of Life Option Act*; and, *An ANCO Practice Atlas—Who We Are, What We Are Doing in Our Practices, and How This Compares to Other Oncology Practices*. Download the presentations at www.anco-online.org/education.html.

ANCO's ASCO Highlights 2016

ANCO's *ASCO Highlights 2016* will take place on Saturday, August 27th at *The Claremont Resort* in Oakland. Faculty from *Stanford University*, the *University of California, Davis*, and the *University of California, San Francisco* will summarize the research and treatment advances reported at ASCO's *Annual Meeting*. A meeting announcement and registration form was distributed in late June. Download the meeting announcement and registration form at www.anco-online.org/ASCOHL2016.pdf.

ANCO's 2016 Hematological Malignancies Updates

ANCO is organizing a series of *Hematological Malignancies Updates* in 2016. The second *Update* will take place on September 17th at the *Hyatt Regency Sacramento* with Bruno Medeiros, M.D., *Stanford University*, Aaron Rosenberg, M.D., *University of California, Davis*, and Rajeev Krishnan, M.D., *University of California, Davis*. The latest research on novel treatment modalities for acute and chronic leukemias, and myeloma, along with case studies for these diagnoses will be presented. The program begins at 8:30AM with breakfast. This meeting is supported by *Janssen Biotech*, *Seattle Genetics*, and *Takeda Oncology*. Space is limited to the first 50 physician or nurse registrants only. Meeting announcements were mailed in mid-August. To register for this meeting, please send your name, affiliation, and e-mail address to execdir@anco-online.org (Subject: 3Q2016 Clinical Meeting) or download and FAX the registration form at www.anco-online.org/3Q2016HemeMalig.pdf.

Additional Education Meetings

Other meetings of possible interest to ANCO member practices are:

August 23rd
For Health Care Professionals: Care Coordination for Older Men Living with Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 6th
Advances in the Treatment of Metastatic Prostate Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 7th

Medical Update on Ovarian Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 9-10th
Palliative Care in Oncology Symposium: Patient-Centered Care Across the Cancer Continuum
 American Society of Clinical Oncology
 San Francisco
 (pallonc.org)

September 10th
1st Annual Symposium on Integrating Immune Therapy & Targeted Therapy into Standards of Care for Solid & Hematologic Malignancies
 Biomedical Learning Institute
 San Francisco
 (www.bmli.com/live/immune/registration.php?x=628c)

September 12th
Preventing Chemotherapy Induced Nausea and Vomiting
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 16-17th
2016 ASH Meeting on Hematologic Malignancies
 American Society of Hematology
 Chicago
 (www.hematology.org/Malignancies/)

September 20th
Update on Advanced Ovarian Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 21st-22nd
ASCO Advocacy Summit 2016—Lead, Engage, Influence
 American Society of Clinical Oncology
 Washington, D.C.
 (www.asco.org/advocacy/2016-advocacy-summit-capitol-hill)

September 23rd
Are You Ready for MACRA? Tools and Resources to Help You Prepare
 American Society of Clinical Oncology
 Alexandria, VA
 (www.surveymonkey.com/r/S652SG8)

September 30th
Advances in the Treatment of Renal Cell Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

September 30th
ICLIO National Conference: Immuno-Oncology—There's More to Discover

ACCC's Institute for Clinical Immuno-Oncology
Philadelphia
(accc-icllo.org/events/iclio-2nd-national-conference/)

October 5th

Update on Triple Negative Breast Cancer (Part I of Living with Triple Negative Breast Cancer)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 19th-21st

ACCC 33rd National Oncology Conference: The How-To Conference for the Cancer Care Team
Association of Community Cancer Centers
St. Louis
(www.accc-cancer.org/meetings/NOC2016.asp)

October 30th-November 2nd

2016 Annual Conference
Medical Group Management Association
San Francisco
(www.mgma.com/annual-conference/why-attend)

December 3rd-6th

58th ASH Annual Meeting & Exposition
American Society of Hematology
San Diego
(www.hematology.org/Annual-Meeting/)

Please contact the ANCO office for more information about these meetings.

are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for October 11th**. Please call José Luis González, ANCO Executive Director, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

Applications for ASCO's Leadership Development Program are now open and must be received by September 23rd. Participants in this year-long *Leadership Program* will gain extensive exposure to the roles and mission of ASCO, its Leadership, and the *Society's* powerful place in developing the future of cancer care, providing both an orientation to ASCO as well as leadership training skills to newer members of the *Society*. Applicants must have completed their final subspecialty training between 2007 and 2012. To learn more about the *Program*, please visit www.asco.org/leadership.

A current Directory of Members is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO Board believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

Board of Directors

The ANCO *Board of Directors* teleconferenced on **June 22nd** to discuss and/or act upon the following issues:

- CMS's proposed CY2017 Medicare Physician Fee Schedule
- California legislation and ballot initiatives
- Membership
- Educational meetings

Contact the ANCO office for additional information on any of these items.

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings

institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Alexion Pharmaceuticals • AMGEN
ARIAD Pharmaceuticals • Astellas Oncology
AstraZeneca • Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pharmacyclics • Prometheus Laboratories, Inc.
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *AbbVie, ARIAD Pharmaceuticals, Clovis Oncology, GenPath Oncology, Guardant Health, Heron Therapeutics, Infinity Pharmaceuticals, Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Merrimack Pharmaceuticals, Prometheus Laboratories, Inc., Sandoz Biopharmaceuticals, Taiho Oncology, and Tesaro* as new Corporate Members for 2016. *Biodesix, Onyx Pharmaceuticals, and Sargass Pharmaceutical Adherence & Compliance (SPAC) International* did not renew their memberships for 2016. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all

member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AbbVie and **Genentech BioOncology** will host a clinical luncheon discussion entitled *Venclexta for Treatment of Previously Treated CLL with 17p Deletion* with Januario Castro, M.D., *UCSD Moores Cancer Center* on August 27th in Berkeley. Please RSVP to Joshua Keough at keough.joshua@gene.com or (650) 867-9361 by August 20th.

Eisai informs ANCO that the *United States Food and Drug Administration* has approved Lenvima in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

Foundation Medicine informs ANCO that it has launched a new assay, *FoundationACT (Assay for Circulating Tumor DNA)*, a rigorously validated and highly accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available.

Heron Therapeutics informs ANCO that the *United States Food and Drug Administration* has approved Sustol in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Merck informs ANCO that the *United States Food and Drug Administration* has approved Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Merck will host a series of webcasts entitled *Keytruda: A New Treatment Option for Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma* with Ezra Cohen, M.D., *UC San Diego Moores Cancer Center* on August 24th, 25th, and 30th. Please RSVP at headandneck.merck.com or to attend in person contact your Merck representative or send an e-mail to GEEM_Operateions@merck.com. Finally, **Merck** informs ANCO that Emend for oral suspension (NDC 0006-3066-03; J8501, 5mg) is now available.

Novartis Oncology informs ANCO that, effectively immediately, Tykerb has been assigned a new NDC number (0078-0671-19; 150 tablets, 250mg).

Clinical Trial News

ASCO's Research Community Forum (formerly the Community Research Forum) is expanding to have a greater impact on research sites from all types of research settings. The *Forum* is inviting researchers and staff from all types of sites to participate in this unique venue with the aim to advance cancer research and support research program management. The *Forum's* annual meeting takes place at ASCO on September 25-26th. Please visit www.asco.org/research-progress/research-community-forum/forum-annual-meeting to learn more and register.

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of Lanreotide Autogel/Depot 120mg plus BSC vs placebo plus BSC for tumor control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumors. (NCT02683941] (KEYNOTE164). Principal Investigator: Pamela Kunz, MD; Contact: Flordeliza Mendoza, (650) 724-2056, flormend@stanford.edu
- A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE164). Principal Investigator: George Fisher, MD, PhD; Contact: Donna Williams, (650) 498-6608, donnacw@stanford.edu
- Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules [END0019]. Principal Investigator: Chris Holsinger, MD; Contact: Priya Hegde, (650) 723-0920, phegde@stanford.edu
- 68Ga-PSMA PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients with Intermediate and High-Risk Prostate Cancer [PROS0075; NCT02678351]. Principal Investigator: Andrei Iagaru, MD; Contact: Omar Rutledge, (650) 721-4089, orutledge@stanford.edu
- A Long Term Follow-Up Umbrella Protocol to Cover NANT Studies to Allow the Collection of Long Term Follow-up Data [NANT201105; NCT00736749]. Principal Investigator: Neyssa

Marina, MD; Contact: Christin New, (650) 497-8815, newc@stanford.edu

- A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor [HEMMPD0026; NCT02426086]. Principal Investigator: Jason Gotlib, MD; Contact: Isabel Reyes, (650) 725-4047, ilreyes@stanford.edu
- A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions [HEMMDS0032; NCT02631070]. Principal Investigator: Peter Greenberg, MD; Contact: Savita Kamble, (650) 723-8594, skamble@stanford.edu
- A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (MPD3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes [HEMMDS0031; NCT02508870]. Principal Investigator: Peter Greenberg, MD; Contact: Savita Kamble, (650) 723-8594, skamble@stanford.edu
- Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) [ECOGS1400; NCT02154490]. Principal Investigator: Heather Wakelee, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu
- NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas [ECOG-ACRIN-EAY131; NCT02465060]. Principal Investigator: James Ford, MD; Contact: Ginna Freehling, (650) 721-8899, gfreehling@stanford.edu
- Phase I AVB-620 in Women with Primary Non-Recurrent Breast Cancer Undergoing Surgery [BRS0061; NCT02391194]. Principal Investigator: Irene Wapnir, MD; Contact: Alifia Hasan, (650) 721-6509, alifia@stanford.edu
- A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment [BRSMTS0024; NCT02492711]. Principal Investigator: Mark Pegram, MD; Contact: Annabel (Grace) Castaneda, (650) 398-7977, annabelc@stanford.edu
- A Phase III, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician's Choice in Germline BRCA Mutation Subsections with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease [BRS0064; NCT01945775].

Principal Investigator: Melinda Telli, MD;
Contact: Janet Pan, (650) 723-0628,
janetpan@stanford.edu

- An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Cytotoxic Chemotherapy in Subjects with Advanced Solid Tumors [BRS0059; NCT02157792]. Principal Investigator: Melinda Telli, MD; Contact: Karen Lau, (650) 723-0658, kkwlu@stanford.edu

- Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma [PBTC047; NCT02717455]. Principal Investigators: Paul Fisher, MD, and Michelle Monje-Deisseroth; Contact: hemonccras@lists.stanford.edu

- A Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy [BRN0030; NCT02546102]. Principal Investigator: Reena Thomas, MD; Contact: Sophie Bertrand, (650) 723-4467, sophieb@stanford.edu

- A Comparison of Overall Survival Post-Cyberknife Radiosurgery Treatment of Patients with 1-3 Versus 4 or More Brain Metastases [BRN0022; NCT01778764]. Principal Investigator: Steven Chang, MD; Contact: Steven Chang, (650) 723-5573, sdchang@stanford.edu

- Single Arm Dose-Escalation Trial of Fructo-Oligosaccharides in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [BMT303; NCT02805075]. Principal Investigator: Andrew Rezvani, MD; Contact: Courtney Greene, (650) 723-0387, cgreene5@stanford.edu

- A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations [BLDR0018; NCT02365597]. Principal Investigator: Sandy Srinivas, MD; Contact: Denise Haas, (650) 736-1252, dhaas@stanford.edu

- Gene Expression That Predicts Radiation Exposure in Humans [VAR0139]. Principal Investigator: Susan Knox, MD; Contact: Susan Knox

- A Phase III International Randomized Study of Transarterial Chemoembolization (TACE) versus Stereotactic Body Radiotherapy (SBRT)/Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma after Initial TACE. [NCT02762266] Principal Investigator: Daniel Chang, MD; Contact: Rachel Freiberg, (650) 725-0438, rachelf@stanford.edu

- A Phase III Double-blinded, Placebo Controlled Study of Xilonix for Improving Survival in Metastatic Colorectal Cancer [COR0011;

clinicaltrials.gov/ct2/show/NCT01767857].

Principal Investigator: George Fisher, MD, PhD;
Contact: Sarah Craig, (650) 723-0186,
scraig2@stanford.edu

- A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma [ECOG4412; NCT01896999]. Principal Investigator: Ranjana Advani, MD; Contact: Caitlin Plahn, (650) 723-3046, cplahn@stanford.edu

- A Phase II Study of Epacadostat (INCB024360) with Pembrolizumab (MK-3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies. Principal Investigator: Pamela Kunz, MD; Contact: Ativ Zomet, (650) 736-0697; azomet@stanford.edu

Further information is available at
cancer.stanford.edu/trials/.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors (CC159520). Contact: Jenna Zhang, (415) 514-8867, jenna.zhang@ucsf.edu

- A Phase I Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Borderline Resectable Pancreatic Cancer (CC#144515). Contact: Marissa Savoie, (415) 353-7683, marissa.savoie@ucsf.edu

- A Phase I, Open-Label, Dose Finding Study of CC-90002, A Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers [CC#15956]. Contact: Armand Harb, (415) 353-7381, armand.harb@ucsf.edu

- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer (CC#159510). Contact: Brittany Bianchi, (415) 885-3725, brittany.bianchi@ucsf.edu

- A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158; CC#159522). Contact: Kevin Shiah, (415) 885-3728, kevin.shiah@ucsf.edu

- A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma. (CC#16451) Contact: Ari Alfaro, (415) 353-7284; alfaroa@ucsf.edu

- A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or

Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer (CC#16459).
Contact: Ari Alfaro, (415) 353-7284;
alfaroa@ucsf.edu

Further information is available at
cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ANCO and MOASC have partnered with SullivanLuallin Group to offer your practice the opportunity to participate in an Oncology-based *Patient Satisfaction Survey*. The Survey is designed to assess your organization's performance in key areas associated with the ACO and PQRS CAPHS Surveys. SullivanLuallin Group's eSurvey: **Online Patient Satisfaction Survey** platform allows you to efficiently and cost-effectively capture how your patients feel about your systems, services, and performance. Download more information and an enrollment form at www.anco-online.org/PtSurvey2016.pdf.

ANCO and MOASC are jointly conducting a 2016 staff salary survey. The survey was e-mail/FAXed to all members in mid-May and is available online at www.anco-online.org/salsrvy.html. A \$50 Visa gift card for respondents is included in this year's survey. Return your completed survey no later than September 30th; results will be analyzed and reported in 4Q2016.

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to <https://apps.asco.org/oncology-practice-central/Survey/#/>.

A *Journal of Oncology Practice* article highlights the latest updates in ASCO's CancerLinQ. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-journal-oncology-practice-articles-highlights-latest-updates. For more information about CancerLinQ, visit www.CancerLinQ.org.

ASCO, the Society of Surgical Oncology (SSO), and the American Society for Radiation Oncology (ASTRO) have issued a joint consensus guideline on margins for breast-conserving surgery with radiation in ductal carcinoma in situ (DCIS). Go to www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/13171 for more information.

ASCO and the Society of Gynecologic Oncology

(SGO) have issued a new clinical practice guideline for neoadjuvant chemotherapy for ovarian cancer. Go to www.asco.org/practice-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/13091 for more information.

ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) have published a joint guidance statement on high-quality palliative care as delivered directly by medical oncology practices. The guidance is published in the *Journal of Oncology Practice*. Learn more at www.asco.org/advocacy-policy/asco-in-action/asco-and-aahpm-joint-statement-provides-guidance-defining-and.

CMS has approved ASCO's *Quality Oncology Practice Initiative* (QOPI) as a qualified clinical data registry (QCDR), a pathway for oncologists to meet the agency's current quality reporting requirements. Oncology practices registered with QOPI will have the opportunity to fulfill CMS's PQRS or QCDR reporting requirements through QOPI. QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the *QOPI Certification Program* to recognize QOPI participants who achieve rigorous standards for cancer care. Go to www.instituteforquality.org/qopi-qcp for more information.

The *Community Oncology Alliance* (COA) has launched the *Advance Practice Provider Network* (CAPP Network) to support advanced practice providers (NPs, PAs, etc.). To join the CAPP Network visit www.communityoncology.org/capp.

NCCN has updated their *Clinical Practice Guidelines in Oncology* and/or *Drugs & Biologics Compendium* for breast cancer screening and diagnosis (V1.2016), gastric cancer (V3.2016), lung cancer screening (V1.2017), non-Hodgkin's lymphomas (chemotherapy order templates), pancreatic adenocarcinoma (V2.2016), small cell lung cancer (V1.2017), testicular cancer (V2.2016), and vulvar cancer (chemotherapy order templates).